Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBT: 2016-2024

Historic EBT for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to -$260.3 million.

  • Rhythm Pharmaceuticals' EBT fell 20.03% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.9 million, marking a year-over-year increase of 25.70%. This contributed to the annual value of -$260.3 million for FY2024, which is 41.36% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported EBT of -$260.3 million as of FY2024, which was down 41.36% from -$184.1 million recorded in FY2023.
  • Rhythm Pharmaceuticals' 5-year EBT high stood at -$69.6 million for FY2021, and its period low was -$260.3 million during FY2024.
  • Its 3-year average for EBT is -$208.5 million, with a median of -$184.1 million in 2023.
  • Data for Rhythm Pharmaceuticals' EBT shows a maximum YoY tumbled of 160.18% (in 2022) over the last 5 years.
  • Rhythm Pharmaceuticals' EBT (Yearly) stood at -$69.6 million in 2021, then tumbled by 160.18% to -$181.1 million in 2022, then fell by 1.65% to -$184.1 million in 2023, then slumped by 41.36% to -$260.3 million in 2024.